Skip to content
Combioxin SA logo — Revolution in the treatment of severe infections

Combioxin SA

Revolution in the treatment of severe infections

Founded 2015 Switzerland Epalinges, Switzerland 3 employees Non Equity Assistance Total: $100.00K Biotechnology, Health Care

General Information

Company Name Combioxin SA
Founded Year 2015
Location Switzerland Epalinges, Switzerland
Founders / Decision Makers
Team member
Employees 3
Industries Biotechnology, Health Care
Funding Stage Non Equity Assistance
Social

BounceWatch is an independent company data service, not affiliated with Combioxin SA. To contact Combioxin SA, visit combioxin.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Combioxin SA compare?

A PDF of Combioxin SA and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Combioxin SA soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Combioxin SA

Combioxin SA is a Swiss-based biotech company founded in 2015, with a focus on developing innovative anti-virulence drugs to treat severe bacterial infections and combat antibiotics resistance. The company's slogan - "Revolution in the treatment of severe infections" - underscores its commitment to transforming the approach to infection treatment. In May 2019, it received a Non Equity Assistance investment from MassChallenge, indicating a growing interest in its groundbreaking work. As Combioxin SA continues to advance as a clinical-stage player in the healthcare industry, its unique approach positions it as a promising prospect for venture capital investment.

Business keywords: biotech, clinical-stage, anti-virulence drugs, severe bacterial infections, antibiotic resistance

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Non Equity Assistance Undisclosed 1
MassChallenge
15 May 2019
Debt Financing Fr.100.00K 1
Foundation for Technological Innovation (FIT)
14 Oct 2016

Combioxin SA Alternatives & Competitors

View All Alternatives
Combioxin SA vs
Micreos
Micreos Switzerland

Micreos is a biotech company focused on discovering and developing recombinant technology

Venture round
21 employees
Biotechnology, Design
Combioxin SA vs

Developing antibiotic free treatment for vaginal infections

Grant
15 employees
Biotechnology, Health Care
Combioxin SA vs
Pattern Bioscience
Pattern Bioscience United States

Our mission is simple: We will improve the world's most important health decisions.

Series C
76 employees
Biotechnology, Health Care

FAQ About Combioxin SA

Revolution in the treatment of severe infections
Combioxin SA was founded in 2015.
Combioxin SA is headquartered in Epalinges, Switzerland.
Combioxin SA operates in Biotechnology and Health Care. Its work centres on biotech, clinical-stage, anti-virulence drugs and severe bacterial infections.
Combioxin SA has approximately 3 employees.
Combioxin SA has completed 2 funding rounds, raising a total of $100.00K. The latest funding stage is Non Equity Assistance.
Top alternatives and competitors to Combioxin SA include Micreos , Gedea Biotech AB, Pattern Bioscience, Adaptive Phage Therapeutics, CytaCoat. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Combioxin SA and Micreos are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Combioxin SA, https://bouncewatch.com/company/combioxin-sa, updated 1 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout